Q2 Earnings Forecast for Cryoport Issued By Leerink Partnrs

Cryoport, Inc. (NASDAQ:CYRX - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for Cryoport in a report issued on Wednesday, May 7th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.21) per share for the quarter, up from their prior estimate of ($0.22). The consensus estimate for Cryoport's current full-year earnings is ($0.99) per share. Leerink Partnrs also issued estimates for Cryoport's Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS and FY2026 earnings at ($0.77) EPS.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to the consensus estimate of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%.

Several other research firms have also issued reports on CYRX. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Cryoport in a research note on Thursday, May 8th. Morgan Stanley decreased their target price on shares of Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Roth Mkm reiterated a "buy" rating and issued a $15.00 target price on shares of Cryoport in a research note on Tuesday, April 1st. Guggenheim reiterated a "buy" rating and issued a $10.00 target price on shares of Cryoport in a research note on Wednesday, April 16th. Finally, UBS Group boosted their price objective on Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

Cryoport Trading Down 7.3%

Shares of NASDAQ:CYRX traded down $0.51 on Monday, hitting $6.47. 400,349 shares of the company's stock were exchanged, compared to its average volume of 541,920. The stock has a market capitalization of $324.39 million, a price-to-earnings ratio of -1.91 and a beta of 1.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport has a 12 month low of $4.58 and a 12 month high of $14.21. The business's 50 day simple moving average is $5.90 and its two-hundred day simple moving average is $6.87.

Hedge Funds Weigh In On Cryoport

Several large investors have recently modified their holdings of CYRX. Cadian Capital Management LP lifted its stake in shares of Cryoport by 14.1% in the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock valued at $38,332,000 after purchasing an additional 609,021 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Cryoport by 11.0% in the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock valued at $32,208,000 after buying an additional 409,353 shares during the period. LPL Financial LLC raised its holdings in shares of Cryoport by 1,366.1% in the 4th quarter. LPL Financial LLC now owns 436,766 shares of the company's stock valued at $3,398,000 after buying an additional 406,976 shares during the period. Norges Bank purchased a new stake in shares of Cryoport in the 4th quarter valued at $2,711,000. Finally, Silvercrest Asset Management Group LLC increased its stake in shares of Cryoport by 77.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company's stock worth $5,780,000 after buying an additional 323,216 shares during the period. Institutional investors and hedge funds own 92.90% of the company's stock.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares of the company's stock, valued at approximately $4,814,359.71. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 19,830 shares of company stock valued at $118,353. Insiders own 10.00% of the company's stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.